GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » PB Ratio

Onconetix (Onconetix) PB Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Onconetix PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-04), Onconetix's share price is $0.2054. Onconetix's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.96. Hence, Onconetix's PB Ratio of today is .

The historical rank and industry rank for Onconetix's PB Ratio or its related term are showing as below:

During the past 5 years, Onconetix's highest PB Ratio was 484.89. The lowest was 0.00. And the median was 0.00.

ONCO's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.55
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Onconetix's average Book Value Per Share Growth Rate was -177.70% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Onconetix was 39.30% per year. The lowest was 39.30% per year. And the median was 39.30% per year.

Back to Basics: PB Ratio


Onconetix PB Ratio Historical Data

The historical data trend for Onconetix's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix PB Ratio Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - - 0.75 -

Onconetix Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 1.42 0.89 - -

Competitive Comparison of Onconetix's PB Ratio

For the Biotechnology subindustry, Onconetix's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onconetix's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's PB Ratio distribution charts can be found below:

* The bar in red indicates where Onconetix's PB Ratio falls into.



Onconetix PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Onconetix's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.2054/-0.964
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Onconetix  (NAS:ONCO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Onconetix PB Ratio Related Terms

Thank you for viewing the detailed overview of Onconetix's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Onconetix (Onconetix) Business Description

Traded in Other Exchanges
Address
201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has a product named Entadfi an FDA approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Executives
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic director BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc 10 percent owner 2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc other: Manager-Cinti Cornerstone Inv. 2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez 10 percent owner, officer: CEO C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh director 201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson officer: Chief Business Officer 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield officer: CFO 11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable director 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202

Onconetix (Onconetix) Headlines

From GuruFocus

Blue Water Biotech Issues Letter to Shareholders

By Marketwired 10-30-2023